Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action
暂无分享,去创建一个
B. Wible | H. Katus | Dierk Thomas | G. Kirsch | E. Ficker | E. Zitron | E. Scholz | S. Kathöfer | J. Kiehn | V. Kreye | W. Schoels | C. Karle | Mary C Kochan | Anna-Britt Wimmer | Kezhong Wu | Bettina C. Hammerling | Bettina C Hammerling | Eckhard K Ficker | Mary C Kochan | Volker A W Kreye | Christoph A Karle | Anna‐Britt Wimmer
[1] H. Katus,et al. Drug binding to aromatic residues in the HERG channel pore cavity as possible explanation for acquired Long QT syndrome by antiparkinsonian drug budipine , 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.
[2] J. Hancox,et al. Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652 , 2003, British journal of pharmacology.
[3] J. Mitcheson. Drug binding to HERG channels: evidence for a ‘non‐aromatic’ binding site for fluvoxamine , 2003, British journal of pharmacology.
[4] H. Katus,et al. Inhibition of cloned HERG potassium channels by the antiestrogen tamoxifen , 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.
[5] Hugo A Katus,et al. The antipsychotic drug chlorpromazine inhibits HERG potassium channels , 2003, British journal of pharmacology.
[6] A. Camm,et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. , 2003, Cardiovascular research.
[7] Stanley Nattel,et al. A comparison of currents carried by HERG, with and without coexpression of MiRP1, and the native rapid delayed rectifier current. Is MiRP1 the missing link? , 2002, The Journal of physiology.
[8] A. Brown,et al. High-affinity blockade of human ether-a-go-go-related gene human cardiac potassium channels by the novel antiarrhythmic drug BRL-32872. , 2001, The Journal of pharmacology and experimental therapeutics.
[9] C R Benedict,et al. Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels. , 2000, The Journal of pharmacology and experimental therapeutics.
[10] Jun Chen,et al. A structural basis for drug-induced long QT syndrome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[11] S. Raimondi,et al. Treatment of childhood acute myelogenous leukemia with an intensive regimen (AML-87) that individualizes etoposide and cytarabine dosages: short- and long-term effects , 2000, Leukemia.
[12] J. Rowe. Treatment of acute myelogenous leukemia in older adults , 2000, Leukemia.
[13] John S. Mitcheson,et al. Trapping of a Methanesulfonanilide by Closure of the Herg Potassium Channel Activation Gate , 2000, The Journal of general physiology.
[14] S. Viskin. Long QT syndromes and torsade de pointes , 1999, The Lancet.
[15] J. Hancox,et al. Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline , 1999, British journal of pharmacology.
[16] M. Keating,et al. MiRP1 Forms IKr Potassium Channels with HERG and Is Associated with Cardiac Arrhythmia , 1999, Cell.
[17] W. Kübler,et al. Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels , 1999, Naunyn-Schmiedeberg's Archives of Pharmacology.
[18] T. Lister,et al. Treatment of acute myelogenous leukemia. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] M. Sanguinetti,et al. A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channel , 1995, Cell.
[20] J. Chant,et al. GTPase cascades choreographing cellular behavior: Movement, morphogenesis, and more , 1995, Cell.
[21] J. Warmke,et al. A family of potassium channel genes related to eag in Drosophila and mammals. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[22] J. Seymour. Induction of hypomagnesemia during amsacrine treatment , 1993, American journal of hematology.
[23] P. Brons,et al. Plasma and cellular pharmacokinetics of m‐AMSA related to in vitro toxicity towards normal and leukemic clonogenic bone marrow cells (CFU‐GM, CFU‐L) , 1993, European journal of haematology.
[24] V. Heinemann,et al. New drugs in the treatment of acute and chronic leukemia with some emphasis on m-AMSA. , 1991, Anticancer research.
[25] M. Sanguinetti,et al. Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents , 1990, The Journal of general physiology.
[26] T. Stijnen,et al. Treatment of acute myelogenous leukemia. An EBMT-EORTC retrospective analysis of chemotherapy versus allogeneic or autologous bone marrow transplantation. , 1989, European journal of cancer & clinical oncology.
[27] S. Marsoni,et al. Amsacrine-associated cardiotoxicity: an analysis of 82 cases. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] S. Foote,et al. The binding of amsacrine to human plasma proteins , 1986, The Journal of pharmacy and pharmacology.
[29] J. Griffin,et al. Amsacrine in refractory acute leukemia. , 1985, Cancer treatment reports.
[30] C. Presant,et al. Sequentially administered 5-azacitidine and amsacrine in refractory adult acute leukemia: a phase I-II trial of the Southeastern Cancer Study Group. , 1985, Cancer treatment reports.
[31] Y. Hasin,et al. Acute electrocardiographic changes induced by amsacrine. , 1984, Cancer treatment reports.
[32] C. Civin,et al. QT interval prolongation and cardiac dysrhythmia in a patient receiving amsacrine. , 1984, Cancer treatment reports.
[33] P. Mclaughlin,et al. Ventricular fibrillation following AMSA. Uncomplicated retreatment following correction of hypokalemia , 1983, Cancer.
[34] B. Sakmann,et al. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches , 1981, Pflügers Archiv.
[35] J. S. Stevenson. In older adults , 1980 .
[36] C. Coltman,et al. Acute ventricular fibrillation and death during infusion of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA). , 1980, Cancer treatment reports.
[37] T. Lister,et al. Treatment of acute leukaemia with m-AMSA in combination with cytosine arabinoside , 2004, Cancer Chemotherapy and Pharmacology.
[38] J. Paxton,et al. Pharmacokinetics of amsacrine in patients receiving combined chemotherapy for treatment of acute myelogenous leukemia , 2004, Cancer Chemotherapy and Pharmacology.
[39] E. Estey,et al. New chemotherapeutic agents in acute myeloid leukemia. , 1996, Leukemia.